Keywords
resistance
gram negative
mechanism of action
How to Cite
Abstract
Ceftazidime-avibactam is a combination administered intravenously, which has activity against gram-negative resistant pathogens such as, for example, Pseudomonas aeruginosas and enterobacteria resistant to carbapenem. This combination is approved for the treatment of complicated urinary infections, intra-abdominal infections, among others. Ceftazidime is a third-generation cephalosporin that together with avibactam, an inhibitor of β-lactamase non-β-lactam, significantly improves its activity against the mentioned pathogens. Ceftazidime-avibactam has excellent activity in vivo and in vitro, has good pharmacological characteristics, related to its pharmacokinetics and pharmacodynamics, and also has a good spectrum, few serious adverse effects and excellent efficacy, safety and tolerability.
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The authors keep the copyright and publication rights in the journal the right of the first publication and this possibility to edit, reproduce, distribute, expose and publicly communicate on the magazine's website. Likewise, it assumes the commitment on any litigation or claim related to the rights of intellectual property, exonerating of responsibility to the Science and Health Magazine of the UCIMED. In addition, you can see how they are published in this journal (eg, Include in an institutional repository or publish it in a book) as long as they clearly indicate the work published for the first time in the magazine Science and Health of the UCIMED.